| Type | Title | Date Released | |
|---|---|---|---|
6-K | NewcelX Ltd. Announces $1.55 Million Private Placement Financing New | ||
6-K | NewcelX Announces Pricing of $1.55 Million Equity Financing at 20% Premium Pricing to Market New | ||
6-K | NewcelX Enters Into Binding Term Sheet to Divest Legacy Mazindol Portfolio to REA Holdings | ||
EFFECT | Form EFFECT | ||
POS AM | SPA | Shares: 500,000 EFFECTIVE, DATED 2026-09-22 | ||
6-K | NewcelX Ltd. Reports Unaudited Interim Financial Results for the Period Ended June 30, 2026 | ||
EFFECT | Form EFFECT | ||
D | Form D | ||
F-3 | SHARE RESALE REGISTRATION | ||
6-K | NewcelX Ltd. Announces $1.4 Million Private Placement Financing | ||
6-K | NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium | ||
6-K | NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes |
